Patterns of resistance development with integrase inhibitors in HIV. - Wikidata - wikimedia - TriplyDB

Patterns of resistance development with integrase inhibitors in HIV.

Patterns of resistance development with integrase inhibitors in HIV.

http://www.wikidata.org/entity/Q41884572

about

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Antiretroviral drugs: critical issues and recent advances Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

P2860

Q34059575-F7782706-C4A5-4BAC-B97B-B235E62955C5 Q34316681-39680226-305E-4E8D-95E6-D313C1287824 Q35169003-6AC2799D-61C3-4B90-88DF-4E7736E66CED Q35789343-C2698B43-7CFE-4F24-8BC3-E70868DD7BF9 Q36020992-1F85AF83-01B8-4E0A-BFEC-9B18D8B9CE9A Q36228871-22689819-D7BE-4FF4-8047-9BAA18E1813C Q36505272-B3330FCC-4D52-4295-B764-0EFFF5F69BFF Q36571812-3EC5FDB2-8022-469A-9E71-3FCDAE86ED6B Q41090342-06C69470-3D1E-4E1F-9DAC-6D2332092A93 Q41884057-E4F642B0-3A34-4BC5-80B7-A9AB2BBADC3A

P2860

Patterns of resistance development with integrase inhibitors in HIV.

http://www.wikidata.org/entity/Q41884572

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Patterns of resistance development with integrase inhibitors in HIV.

@en

type

label

Patterns of resistance development with integrase inhibitors in HIV.

@en

prefLabel

Patterns of resistance development with integrase inhibitors in HIV.

@en

P1433

Q41884572-A1F2A21B-7110-45A2-A536-BA349436100E

P1476

Q41884572-B8F3C0B1-553A-4FE2-82EA-537E3997FF2B

P2093

Q41884572-29AEA6B1-3B81-4D6D-B5EA-823CDBC35252

Q41884572-7FFE99A7-A2F6-42ED-8027-6442519C27F1

Q41884572-83EE09A6-7535-4ADF-AB54-4423C586C4D8

P2860

Q41884572-0C791921-BDE4-4E66-8CCE-4D3A12AFEA6A

Q41884572-0D3BAD68-B1F2-4413-99CA-52D3B8793ACB

Q41884572-113CBA12-4B4A-483F-8D17-013CB1A2E873

Q41884572-130D4C68-C54D-4DEC-AA29-4E571C6BD2E6

Q41884572-1DDE61FA-2B43-4A82-B82A-DE8A31618E29

Q41884572-2239C905-1DAE-4DBA-93E3-6073B6D61688

Q41884572-2970D8B7-B3D7-4F40-9DD4-C13A0E2802E2

Q41884572-2D4B263B-BB5D-4FBD-90C7-C5A7B1CB2379

Q41884572-3742C1BC-AE9A-4B34-95D0-2B6742410141

Q41884572-3CF67F1D-B3F9-42F6-93CE-1F89DC31234B

P304

Q41884572-A49ABE0D-1414-4AC6-9E3D-9BCB896B06E0

P31

Q41884572-678C09A6-F0B6-40C3-9682-05BE2129F8BD

P356

Q41884572-849A0C3F-238F-4C89-A6A7-4033FBE38C11

P407

Q41884572-E4A481DC-04FF-45DF-B771-CC5C067B0C2C

P478

Q41884572-62BF0F93-4A12-46A4-89F2-666B64B9A127

P577

Q41884572-671D32F9-876A-4088-98EC-08D81346AF20

P698

Q41884572-34D8C2F4-5F5A-42C5-ABE2-033A43D1DC24

P932

Q41884572-F4D2B0D8-3DC0-4405-827F-686966ABADBA

P356

P1433

Infection and Drug Resistance

P1476

Patterns of resistance development with integrase inhibitors in HIV.

@en

P2093

Jean L Mbisa

http://www.w3.org/2001/XMLSchema#string

Patricia A Cane

http://www.w3.org/2001/XMLSchema#string

Supang A Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes

Retroviral intasome assembly and inhibition of DNA strand transfer

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition

Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences

Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding

Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein.

Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases

P304

65-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IDR.S7775

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21694910

http://www.w3.org/2001/XMLSchema#string

P932

3108751

http://www.w3.org/2001/XMLSchema#string